Personal > Centre d'investigació

Julio Castaño Cardoso

Julio Castaño Cardoso

jcastano@cmrb.eu


Julio Castaño es va llicenciar en Biologia per la Universitat de Barcelona. L'any 2000 va obtenir una beca doctoral del Ministeri d'Educació i Ciència i va ingressar en el programa de Doctorat en Bioquímica i Biologia Molecular a la Universitat Autònoma de Barcelona, sota la supervisió de la Dra. Mireia Duñach i el Dr. Antonio García de Herreros . Durant la seva tesi de doctorat va estudiar el paper de la via Wnt i les unions adherents en el càncer colorectal. El 2006 es va traslladar al CIBBIM, a l'Hospital Vall d'Hebron (Barcelona) per un post-doct al laboratori del Dr. Simo Schwartz Jr. recolzat per una beca Juan de la Cierva, estudiant els mecanismes epigenètics implicats en la remodelació de la cromatina i l'expressió gènica.

Des de l'any 2008 al 2011 va treballar al Centre de Medicina Regenerativa de Barcelona (CMR[B]) com a Tècnic Superior. Principalment va estar involucrat en un projecte enfocat en el paper dels enzims modificadors d'histones en la pluripotència i la diferenciació de cèl•lules mare. De 2011 a 2013, va treballar a la Fundació Inbiomed, al Laboratori de Hematopoesi i Trastorns de la Sang, com Lab Manager-Staff Scientist. Aquí no només va contribuir a iniciar i organitzar el nou Laboratori de Hematopoesi i Trastorns de la Sang sinó que també va participar en un projecte enfocat a convertir directament les cèl•lules mare hematopoètiques en neurones.

El 2013 es va traslladar a l'Institut de Recerca de Leucèmia Josep Carreras, al nou Departament de Cèl•lules Mare, Càncer mesenquimal i Desenvolupament com a Investigador Associat-Lab manager.

L'any 2017 es va incorporar a CMR[B] associat a un projecte de recerca de PERIS "Cardiopoyesis amb biomatrices per regenerar la cicatriu postinfart: del banc a la capçalera", finançat pel Departament de Salut de la Generalitat de Catalunya. Dins d'aquest projecte, Julio desenvoluparà protocols més eficients per a la diferenciació de cardiomiòcits a partir d'iPSC, i generarà línies editades per CRIPSR / CAS9 de iPSC per ajudar a aquest procés.



Publicacions seleccionades

  • Castaño J, Aranda S, Bueno C, Calero-Nieto FJ, Mejia-Ramirez E, Mosquera JL, Blanco E, Wang X, Prieto C, Zabaleta L, Mereu E, Rovira M, Jiménez-Delgado S, Matson DR, Heyn H, Bresnick EH, Göttgens B, Di Croce L, Menendez P, Raya A and Giorgetti A. (2019) GATA2 Promotes Hematopoietic Development and Represses Cardiac Differentiation of Human Mesoderm. Stem Cell Rep Epub 2019, Aug 8.
  • Gentinella A, Morón-Duran FD, Fuentes P, Zweig-Rocha G, Riaño-Canalias F, Pelletier J, Ruiz M, Turón G, Castaño J, Tauler A, Bueno C, Menéndez P, Kozma SC, Thomas G. (2017) Autogenous Control of 5TOP mRNA Stability by 40S Ribosomes. Molecular Cell. 67(1):55-70
  • Romero-Moya D, Santos-Ocaña C, Castaño J, Garrabou G, Rodríguez-Gómez JA, Ruiz-Bonilla V, Perdiguero E, Bueno B, Moren-Nuñez C, González-Rodriguez P, Giorgetti A, Prieto C, Muñoz-López A, Fernández-Ayala D, Cascajo MV, Velasco I, López-Barneo J, Cardellach J, Artuch R, Muñoz-Cánoves P, Navas P, Menéndez P. (2017) Genetic rescue of mitochondrial and skeletal muscle impairment in an iPSC model of coenzyme Q10 deficiency. Stem cells 35(7):1687-1703
  • Díaz de la Guardia R, Lopez-Millan B, Lavoie J, Bueno C, Castaño J, Gómez-Casares M, Vives S, Palomo L, Juan M, Delgado J, Blanco L, Nomdedeu J, Chaparro A, Fuster JL, Anguita E, Rosu-Myles M, Menéndez P. (2017) Detailed characterization of mesenchymal stem/stromal cells from a large cohort of AML patients demonstrates a definitive link to treatment outcomes. Stem Cell Reports 8(6):1573-1586.
  • Castaño J, Bueno C, Jiménez-Delgado S, Roca-Ho H, Torres-Ruíz R, Rodríguez-Perales S, Fraga MF, Fernandez AF, Menendez P. (2017) Generation and characterization of a human iPSC cell line expressing inducible Cas9. Stem Cell Research 21:137-140.
  • Torres-Ruiz R, Martinez-Lage M, Martin MC, Garcia A, Bueno C, Castaño J, Ramirez JC, Menendez P, Cigudosa JC, Rodriguez-Perales S. (2017) Efficient generation of chromosomal translocations in human primary stem cells using CRISPR-Cas9. Stem Cell Reports 8(5):1408-1420.
  • Giorgetti A, Castaño J, Bueno C, Díaz de la Guardia R, Delgado M, Bigas A, Espinosa L, Menendez P. (2017) Proinflammatory signals are insufficient to drive definitive hematopoietic specification of human HSCs in vitro. Exp Hematol. 45:85-93.
  • Romero-Moya D, Castaño J, Santos-Ocaña C, Navas P, Menendez P. (2016) Generation, genome edition and characterization of iPSC lines from a patient with coenzyme Q10 deficiency harboring a heterozygous mutation in COQ4 gene. Stem Cell Research pii: S1873-5061(16)30122-2
  • Castaño J, Herrero AB, Bursen A, González F, Marschalek R, Gutiérrez N, Menendez P. (2016) Expression of MLL.AF4 or AF4.MLL fusion does not impact the efficiency of DNA damage repair. Oncotarget 7(21):30440-52.
  • Prieto C, Stam RW, Agraz-Doblas A, Ballerini P, Camos M, Castaño J, Marschalek R, Bursen A, Varela I, Bueno C, Menéndez P. (2016) Activated KRAS cooperates with MLLAF4 to promote extramedullary engraftment and migration of cord blood CD34+ HSPC but is not sufficient to initiate leukemia. Cancer Research 76(8): 2478-89.
  • Castaño J, Sese B, Boue S, Morera C, Bonet-Costa C, Roque A, Martí M, Jordan A, Barrero MJ. (2016) SETD7 regulates the differentiation of human embryonic stem cells. Plos One 11(2):e0149502
  • Bueno C, Sardina JL, Di Stefano B, Romero-Moya D, Muñoz-López A, Ariza L, Chillón MC, Balanzategui A, Castaño J, Herreros A, Fraga MF, Fernández A, Granada I, Quintana-Bustamante O, Segovia JC, Nishimura K, Ohtaka M, Nakanishi M, Graf T, Menendez P. (2015) Reprogramming human B cells into induced pluripotent stem cells and its enhancement by C/EBPα. Leukemia 2015 Oct 26.
  • Castaño J, Menendez P, Bruzos-Cidon C, Straccia M, Sousa A, Zabaleta L, Vazquez N, Zubiarrain A, Sonntag KC, Ugedo L, Carvajal-Vergara X, Canals JM, Torrecilla M, Sanchez-Pernaute R, Giorgetti A. (2014) Fast and efficient neural conversion of human hematopoietic cells. Stem Cell Reports 3(6):1118-31.
  • Velasco I, Salazar P, Giorgetti A, Ramos-Mejía V, Castaño J, Romero-Moya D, Menendez P. (2014) Concise review: Generation of neurons from somatic cells of healthy individuals and neurological patients through induced pluripotency or direct conversion. Stem Cells 32(11):2811-7.
  • Davalos V(*), Suarez-Lopez L(*), Castaño J, Messent A, Abasolo I, Fernandez Y, Guerra-Moreno A, Espin E, Armengol M, Musulen E, Ariza A, Sayos J, Arango D, Schwartz S. (2012) hSMC2, a Core Subunit of Human Condensin Complex, is a Novel Transcriptional Target of the Wnt Signaling Pathway and a New Therapeutic Target. Journal of Biological Chemistry 287(52):43472-81.
  • Giorgetti A, Marchetto MC, Li M, Yu D, Fazzina R, Mu Y, Adamo A, Paramonov I, Cardoso JC, Monasterio MB, Bardy C, Cassiani-Ingoni R, Liu GH, Gage FH, Izpisua Belmonte JC. (2012) Cord Blood-derived neuronal cells by ectopic expression of SOX2 and c-MYC. Proc Natl Acad Sci U S A. 109(31):12556-61.
  • Adamo A, Sesé B, Boue S, Castaño J, Paramonov I, Barrero MJ, Izpisua Belmonte JC. (2011) LSD1 regulates the balance between self-renewal and differentiation in human embryonic stem cells. Nature Cell Biology 13(6);652-659.
  • Dopeso H, Mateo-Lozano S, Mazzolini R, Rodrigues P, Lagares-Tena L, Ceron J, Romero J, Esteves M, Landolfi S, Hernández-Losa J, Castaño J, Wilson AJ, Ramon y Cajal S, Mariadason JM, Schwartz S Jr, Arango D. (2009) The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis. Cancer Research 68(18);7430-7438.
  • Castaño J, Davalos V, Schwartz S Jr, Arango D. (2008) EPH receptors in cancer. Histolology and Histopathology 23(4); 1011-1023.
  • Davalos V, Dopeso H, Castaño J, Wilson AJ, Vilardell F, Romero-Gimenez J, Espín E, Armengol M, Capella G, Mariadason JM, Aaltonen LA, Schwartz S Jr, Arango D. (2006) EPHB4 and survival of colorectal cancer patients. Cancer Research 66(18);8943-8948.
  • Castaño J, Solanas G, Casagolda D, Raurell I, Villagrasa P, Bustelo XR, García de Herreros A, Duñach M (2006) Specific phosphorylation of p120-catenin regulatory domain differently modulates its binding to RhoA. Molecular and Cellular Biology 27(5);1745-1754.
  • Raurell I, Castaño J, Franci C, Garcia de Herreros A, Duñach M. (2005) Presenilin-1 interacts with plakoglobin and enhances plakoglobin-Tcf-4 association: Implications for the regulation of beta -catenin/Tcf-4-dependent transcription. Journal of Biological Chemistry 281(3);1401-1411.
  • Solanas G, Miravet S, Casagolda D, Castaño J, Raurell I, Corrionero A, de Herreros AG, Duñach M. (2004) beta- Catenin and plakoglobin N- and C-tails determine ligand specificity. Journal of Biological Chemistry 279 (48);49849-49856.
  • Piedra J, Miravet S, Castaño J, Palmer HG, Heisterkamp N, Garcia de Herreros A, Duñach M. (2003) p120 Catenin- associated Fer and Fyn tyrosine kinases regulate beta-catenin Tyr-142 phosphorylation and beta-catenin- alpha-catenin Interaction. Molecular and Cellular Biology 23(7); 2289-2297.
  • Miravet S, Piedra J, Castaño J, Raurell I, Franci C, Duñach M, Garcia de Herreros A. (2003) Tyrosine phosphorylation of plakoglobin causes contrary effects on its association with desmosomes and adherens junction components and modulates beta-catenin-mediated transcription. Molecular and Cellular Biology 23(20); 7391-7402.
  • Castaño J, Raurell I, Piedra JA, Miravet S, Duñach M, Garcia de Herreros. (2002) beta-catenin N- and C-terminal tails modulate the coordinated binding of adherens junction proteins to beta-catenin. Journal of Biological Chemistry 277(35);31541-31550.
  • Piedra J, Martinez D, Castaño J, J, Miravet S, Duñach M, de Herreros AG. (2001) Regulation of beta-catenin structure and activity by tyrosine phosphorylation. Journal of Biological Chemistry 276(23);20436-20443.



© Centre de Medicina Regenerativa de Barcelona 2009-2019 - Nota legal - Política de cookies - Crèdits - Accessibilitat